Biggest News Aggregation in the World
📰 Nasdaq Prof News

Page 2 - Nasdaq Prof News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Prof. Real-time updates on events, politics, business and more.

Raymond James Weighs in on Profound Medical Corp.'s FY2027 Earnings (NASDAQ:PROF)

Profound Medical Corp. (NASDAQ:PROF – Get Rating) – Analysts at Raymond James issued their FY2027 earnings per share (EPS) estimates for Profound Medical in a research note issued on Thursday, June 15th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $2.87 per share for the year. Raymond James currently has […]
United States Raymond James Raymond James Financial Services Advisors Inc Thompson Davis Jefferies Financial Group Cetera Advisor Networks

Raymond James Boosts Profound Medical (NASDAQ:PROF) Price Target to $20.00

Profound Medical (NASDAQ:PROF – Get Rating) had its target price boosted by Raymond James from $17.00 to $20.00 in a report published on Monday morning, BayStreet.CA reports. They currently have a strong-buy rating on the stock. Separately, Jefferies Financial Group lowered shares of Profound Medical from a buy rating to a hold rating and boosted […]
United States Raymond James Jefferies Financial Group Thompson Davis Raymond James Financial Services Advisors Inc Cetera Advisor Networks

Profound Medical (PROF) Set to Announce Quarterly Earnings on Wednesday

Profound Medical (NASDAQ:PROF – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 10th. Analysts expect Profound Medical to post earnings of ($0.32) per share for the quarter. Profound Medical (NASDAQ:PROF – Get Rating) last released its quarterly earnings data on Tuesday, March 7th. The company […]
United States Raymond James Gilder Gagnon Howe Co Jefferies Financial Group America Corp Raymond James Financial Services Advisors Inc
Source: wkrb13.com

Profound Medical (NASDAQ:PROF) Cut to Hold at Jefferies Financial Group

Jefferies Financial Group cut shares of Profound Medical (NASDAQ:PROF – Get Rating) from a buy rating to a hold rating in a report published on Tuesday, Marketbeat.com reports. The brokerage currently has $10.00 target price on the stock, up from their prior target price of $5.50. Jefferies Financial Group also issued estimates for Profound Medical’s […]
United States Raymond James Cetera Advisor Networks America Corp Company Profile Crestwood Advisors Group

Brokerages Anticipate Profound Medical Corp. (NASDAQ:PROF) Will Announce Quarterly Sales of $2.00 Million

Equities research analysts predict that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will report $2.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Profound Medical’s earnings. Profound Medical reported sales of $2.63 million in the same quarter last year, which indicates a negative year […]
United States Raymond James Zacks Investment Research Alliance Global Partners Company Profile Get Rating Letko Brosseau Associates Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

-$0.45 EPS Expected for Profound Medical Corp. (NASDAQ:PROF) This Quarter

Equities analysts forecast that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will post ($0.45) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Profound Medical’s earnings, with estimates ranging from ($0.52) to ($0.38). Profound Medical posted earnings of ($0.37) per share during the same quarter […]
United States Raymond James National Bank Gagnon Securities Zacks Investment Research Profound Medical

Profound Medical (NASDAQ:PROF) PT Set at $22.00 by Raymond James

Profound Medical (NASDAQ:PROF – Get Rating) has been given a $22.00 price objective by research analysts at Raymond James in a report issued on Monday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price target points to a potential upside of 195.30% from the company’s previous close. Several other […]
United States Raymond Jame Raymond James Letko Brosseau Associates Inc Gagnon Securities Deerfield Management Companylp Series

$1.50 Million in Sales Expected for Profound Medical Corp. (NASDAQ:PROF) This Quarter

Wall Street analysts predict that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will report sales of $1.50 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Profound Medical’s earnings. Profound Medical reported sales of $710,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 111.3%. […]
United States Raymond James Harbor Advisors Zacks Investment Research De Shaw Co Company Profile Get Rating

Profound Medical (NASDAQ:PROF) Price Target Lowered to $22.00 at Raymond James

Profound Medical (NASDAQ:PROF – Get Rating) had its target price reduced by Raymond James from $23.00 to $22.00 in a report published on Monday morning, BayStreet.CA reports. Raymond James currently has an outperform rating on the stock. PROF has been the topic of a number of other reports. Zacks Investment Research cut Profound Medical from […]
Raymond James Letko Brosseau Associates Inc Raymond James Financial Services Advisors Inc Geode Capital Management Zacks Investment Research Raymond James Associates

Profound Medical (NASDAQ:PROF) Announces Quarterly Earnings Results

Profound Medical (NASDAQ:PROF – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.14), MarketWatch Earnings reports. Profound Medical had a negative net margin of 320.56% and a negative return on equity of 30.45%. During the […]
Thomson Reuter Raymond James Exchange Commission Zacks Investment Research Millennium Management Profound Medical

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science